Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated:  12/31/1969
Lakeland Medical Center Saint Joseph
mi
from
Saint Joseph, MI
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated: 12/31/1969
Lakeland Medical Center Saint Joseph
mi
from
Saint Joseph, MI
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated:  12/31/1969
Capital Region Southwest Campus
mi
from
Jefferson City, MO
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated: 12/31/1969
Capital Region Southwest Campus
mi
from
Jefferson City, MO
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated:  12/31/1969
Vidant Oncology-Kinston
mi
from
Kinston, NC
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated: 12/31/1969
Vidant Oncology-Kinston
mi
from
Kinston, NC
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated:  12/31/1969
HSHS Sacred Heart Hospital
mi
from
Eau Claire, WI
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated: 12/31/1969
HSHS Sacred Heart Hospital
mi
from
Eau Claire, WI
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated:  12/31/1969
Cancer Care Specialists of Illinois - Decatur
mi
from
Decatur, IL
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated: 12/31/1969
Cancer Care Specialists of Illinois - Decatur
mi
from
Decatur, IL
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated:  12/31/1969
Ascension Saint John Hospital
mi
from
Detroit, MI
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated: 12/31/1969
Ascension Saint John Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated:  12/31/1969
Promedica Flower Hospital
mi
from
Sylvania, OH
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated: 12/31/1969
Promedica Flower Hospital
mi
from
Sylvania, OH
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated:  12/31/1969
Miami Valley Hospital North
mi
from
Dayton, OH
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated: 12/31/1969
Miami Valley Hospital North
mi
from
Dayton, OH
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated:  12/31/1969
Saint Vincent Hospital Cancer Center at Oconto Falls
mi
from
Oconto Falls, WI
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated: 12/31/1969
Saint Vincent Hospital Cancer Center at Oconto Falls
mi
from
Oconto Falls, WI
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated:  12/31/1969
OptumCare Cancer Care at Fort Apache
mi
from
Las Vegas, NV
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated: 12/31/1969
OptumCare Cancer Care at Fort Apache
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated:  12/31/1969
Marshfield Medical Center-Marshfield
mi
from
Marshfield, WI
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated: 12/31/1969
Marshfield Medical Center-Marshfield
mi
from
Marshfield, WI
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated:  12/31/1969
Marshfield Medical Center-Rice Lake
mi
from
Rice Lake, WI
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated: 12/31/1969
Marshfield Medical Center-Rice Lake
mi
from
Rice Lake, WI
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated:  12/31/1969
Ascension Saint Mary's Hospital
mi
from
Saginaw, MI
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated: 12/31/1969
Ascension Saint Mary's Hospital
mi
from
Saginaw, MI
Click here to add this to my saved trials
Testing Accountability in Patient Adherence
Testing Accountability in Patient Adherence
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Testing Accountability in Patient Adherence
Testing Accountability in Patient Adherence
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Study of Abiraterone Acetate and Prednisone in Combination With Cabazitaxel in Patients With Prostate Cancer
Phase II Study of Abiraterone Acetate and Prednisone in Combination With Cabazitaxel, Compared to Cabazitaxel Alone, in Patients With Metastatic Castrate Resistant Prostate Cancer.
Status: Enrolling
Updated:  12/31/1969
University of Colorado Cancer Center
mi
from
Aurora, CO
Study of Abiraterone Acetate and Prednisone in Combination With Cabazitaxel in Patients With Prostate Cancer
Phase II Study of Abiraterone Acetate and Prednisone in Combination With Cabazitaxel, Compared to Cabazitaxel Alone, in Patients With Metastatic Castrate Resistant Prostate Cancer.
Status: Enrolling
Updated: 12/31/1969
University of Colorado Cancer Center
mi
from
Aurora, CO
Click here to add this to my saved trials
Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast Cancer
Phase I Trial of Intratumoral Administration of a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast Cancer
Phase I Trial of Intratumoral Administration of a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]
A Phase II, Multicenter, Single-arm Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
HonorHealth Research Institute - Pima Center
mi
from
Scottsdale, AZ
A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]
A Phase II, Multicenter, Single-arm Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
HonorHealth Research Institute - Pima Center
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]
A Phase II, Multicenter, Single-arm Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Stanford University and Lucile Packard Children's Hospital
mi
from
Palo Alto, CA
A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]
A Phase II, Multicenter, Single-arm Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Stanford University and Lucile Packard Children's Hospital
mi
from
Palo Alto, CA
Click here to add this to my saved trials
A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]
A Phase II, Multicenter, Single-arm Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
The Angeles Clinic and Research Institute, Santa Monica Office
mi
from
Santa Monica, CA
A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]
A Phase II, Multicenter, Single-arm Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
The Angeles Clinic and Research Institute, Santa Monica Office
mi
from
Santa Monica, CA
Click here to add this to my saved trials
A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]
A Phase II, Multicenter, Single-arm Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
University of Colorado
mi
from
Aurora, CO
A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]
A Phase II, Multicenter, Single-arm Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
University of Colorado
mi
from
Aurora, CO
Click here to add this to my saved trials
A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]
A Phase II, Multicenter, Single-arm Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Yale University School of Medicine
mi
from
New Haven, CT
A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]
A Phase II, Multicenter, Single-arm Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Yale University School of Medicine
mi
from
New Haven, CT
Click here to add this to my saved trials
A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]
A Phase II, Multicenter, Single-arm Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Georgetown University
mi
from
Washington,
A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]
A Phase II, Multicenter, Single-arm Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Georgetown University
mi
from
Washington,
Click here to add this to my saved trials
A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]
A Phase II, Multicenter, Single-arm Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Florida Hospital Cancer Inst
mi
from
Orlando, FL
A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]
A Phase II, Multicenter, Single-arm Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Florida Hospital Cancer Inst
mi
from
Orlando, FL
Click here to add this to my saved trials
A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]
A Phase II, Multicenter, Single-arm Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Hematology Oncology Associates of Treasure Coast
mi
from
Port Saint Lucie, FL
A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]
A Phase II, Multicenter, Single-arm Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Hematology Oncology Associates of Treasure Coast
mi
from
Port Saint Lucie, FL
Click here to add this to my saved trials
A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]
A Phase II, Multicenter, Single-arm Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Florida Cancer Specialists
mi
from
Saint Petersburg, FL
A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]
A Phase II, Multicenter, Single-arm Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Florida Cancer Specialists
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]
A Phase II, Multicenter, Single-arm Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
H. Lee Moffitt Cancer Center & Research Inst, Inc
mi
from
Tampa, FL
A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]
A Phase II, Multicenter, Single-arm Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
H. Lee Moffitt Cancer Center & Research Inst, Inc
mi
from
Tampa, FL
Click here to add this to my saved trials
A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]
A Phase II, Multicenter, Single-arm Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Northwest Georgia Oncology Centers, P.C.
mi
from
Carrollton, GA
A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]
A Phase II, Multicenter, Single-arm Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Northwest Georgia Oncology Centers, P.C.
mi
from
Carrollton, GA
Click here to add this to my saved trials
A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]
A Phase II, Multicenter, Single-arm Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
University of Chicago Medical Center
mi
from
Chicago, IL
A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]
A Phase II, Multicenter, Single-arm Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
University of Chicago Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]
A Phase II, Multicenter, Single-arm Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Dartmouth Hitchcock Medical Center/Norris Cotton Cancer Center
mi
from
Lebanon, NH
A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]
A Phase II, Multicenter, Single-arm Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Dartmouth Hitchcock Medical Center/Norris Cotton Cancer Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]
A Phase II, Multicenter, Single-arm Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]
A Phase II, Multicenter, Single-arm Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]
A Phase II, Multicenter, Single-arm Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Duke University Health Systems
mi
from
Durham, NC
A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]
A Phase II, Multicenter, Single-arm Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Duke University Health Systems
mi
from
Durham, NC
Click here to add this to my saved trials
A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]
A Phase II, Multicenter, Single-arm Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Carolina BioOncology Institute; Can Therapy & Res Ctr
mi
from
Huntersville, NC
A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]
A Phase II, Multicenter, Single-arm Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Carolina BioOncology Institute; Can Therapy & Res Ctr
mi
from
Huntersville, NC
Click here to add this to my saved trials
A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]
A Phase II, Multicenter, Single-arm Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Ohio State Uni Hospital
mi
from
Columbus, OH
A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]
A Phase II, Multicenter, Single-arm Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Ohio State Uni Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]
A Phase II, Multicenter, Single-arm Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Oncology Hematology Care, Inc.
mi
from
Hamilton, OH
A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]
A Phase II, Multicenter, Single-arm Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Oncology Hematology Care, Inc.
mi
from
Hamilton, OH
Click here to add this to my saved trials
A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]
A Phase II, Multicenter, Single-arm Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Penn State Univ. Milton S. Hershey Medical Center; MSHMC Cardiology
mi
from
Hershey, PA
A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]
A Phase II, Multicenter, Single-arm Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Penn State Univ. Milton S. Hershey Medical Center; MSHMC Cardiology
mi
from
Hershey, PA
Click here to add this to my saved trials
A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]
A Phase II, Multicenter, Single-arm Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Penn Presbyterian Medical Center; Abramson Cancer Center
mi
from
Philadelphia, PA
A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]
A Phase II, Multicenter, Single-arm Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Penn Presbyterian Medical Center; Abramson Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]
A Phase II, Multicenter, Single-arm Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Univ of Pennsylvania
mi
from
Philadelphia, PA
A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]
A Phase II, Multicenter, Single-arm Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]
A Phase II, Multicenter, Single-arm Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
SCRI - Tennessee Oncology
mi
from
Nashville, TN
A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]
A Phase II, Multicenter, Single-arm Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
SCRI - Tennessee Oncology
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]
A Phase II, Multicenter, Single-arm Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Huntsman Cancer Institute at University of Utah
mi
from
Salt Lake City, UT
A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]
A Phase II, Multicenter, Single-arm Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Huntsman Cancer Institute at University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]
A Phase II, Multicenter, Single-arm Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Virginia Cancer Institute
mi
from
Richmond, VA
A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]
A Phase II, Multicenter, Single-arm Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Virginia Cancer Institute
mi
from
Richmond, VA
Click here to add this to my saved trials
A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]
A Phase II, Multicenter, Single-arm Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
University of Washington/Seattle Cancer Care Alliance
mi
from
Seattle, WA
A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]
A Phase II, Multicenter, Single-arm Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
University of Washington/Seattle Cancer Care Alliance
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]
A Phase II, Multicenter, Single-arm Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Sint Augustinus Wilrijk
mi
from
Wilrijk,
A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]
A Phase II, Multicenter, Single-arm Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Sint Augustinus Wilrijk
mi
from
Wilrijk,
Click here to add this to my saved trials
Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers
A Randomized Trial of a Family Caregiver Palliative Care Intervention
Status: Enrolling
Updated:  12/31/1969
City of Hope Medical Center
mi
from
Duarte, CA
Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers
A Randomized Trial of a Family Caregiver Palliative Care Intervention
Status: Enrolling
Updated: 12/31/1969
City of Hope Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy
A Phase II Study of the Beta-blocker Propranolol Alone and With Chemotherapy in Patients Receiving Neoadjuvant Treatment for Newly Diagnosed Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Columbia University Medical Center
mi
from
New York, NY
Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy
A Phase II Study of the Beta-blocker Propranolol Alone and With Chemotherapy in Patients Receiving Neoadjuvant Treatment for Newly Diagnosed Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Preventing Nephrotoxicity and Ototoxicity From Osteosarcoma Therapy
Pilot Study to Prevent Nephrotoxicity of High-Dose Methotrexate by Prolonging the Infusion Duration and Prevent Nephrotoxicity and Ototoxicity of Cisplatin With Pantoprazole in Children, Adolescents and Young Adults With Osteosarcoma
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Preventing Nephrotoxicity and Ototoxicity From Osteosarcoma Therapy
Pilot Study to Prevent Nephrotoxicity of High-Dose Methotrexate by Prolonging the Infusion Duration and Prevent Nephrotoxicity and Ototoxicity of Cisplatin With Pantoprazole in Children, Adolescents and Young Adults With Osteosarcoma
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Ohio Colorectal Cancer Prevention Initiative
Ohio Colorectal Cancer Prevention Initiative: Universal Screening for Lynch Syndrome
Status: Enrolling
Updated:  12/31/1969
Akron General Medical Center
mi
from
Akron, OH
Ohio Colorectal Cancer Prevention Initiative
Ohio Colorectal Cancer Prevention Initiative: Universal Screening for Lynch Syndrome
Status: Enrolling
Updated: 12/31/1969
Akron General Medical Center
mi
from
Akron, OH
Click here to add this to my saved trials
Ohio Colorectal Cancer Prevention Initiative
Ohio Colorectal Cancer Prevention Initiative: Universal Screening for Lynch Syndrome
Status: Enrolling
Updated:  12/31/1969
Akron City/St. Thomas Hospital (Summa Health System)
mi
from
Akron, OH
Ohio Colorectal Cancer Prevention Initiative
Ohio Colorectal Cancer Prevention Initiative: Universal Screening for Lynch Syndrome
Status: Enrolling
Updated: 12/31/1969
Akron City/St. Thomas Hospital (Summa Health System)
mi
from
Akron, OH
Click here to add this to my saved trials
Ohio Colorectal Cancer Prevention Initiative
Ohio Colorectal Cancer Prevention Initiative: Universal Screening for Lynch Syndrome
Status: Enrolling
Updated:  12/31/1969
Summa Barberton (Summa Health System)
mi
from
Barberton, OH
Ohio Colorectal Cancer Prevention Initiative
Ohio Colorectal Cancer Prevention Initiative: Universal Screening for Lynch Syndrome
Status: Enrolling
Updated: 12/31/1969
Summa Barberton (Summa Health System)
mi
from
Barberton, OH
Click here to add this to my saved trials
Ohio Colorectal Cancer Prevention Initiative
Ohio Colorectal Cancer Prevention Initiative: Universal Screening for Lynch Syndrome
Status: Enrolling
Updated:  12/31/1969
Mercy Clermont
mi
from
Batavia, OH
Ohio Colorectal Cancer Prevention Initiative
Ohio Colorectal Cancer Prevention Initiative: Universal Screening for Lynch Syndrome
Status: Enrolling
Updated: 12/31/1969
Mercy Clermont
mi
from
Batavia, OH
Click here to add this to my saved trials
Ohio Colorectal Cancer Prevention Initiative
Ohio Colorectal Cancer Prevention Initiative: Universal Screening for Lynch Syndrome
Status: Enrolling
Updated:  12/31/1969
Mercy Medical Center
mi
from
Canton, OH
Ohio Colorectal Cancer Prevention Initiative
Ohio Colorectal Cancer Prevention Initiative: Universal Screening for Lynch Syndrome
Status: Enrolling
Updated: 12/31/1969
Mercy Medical Center
mi
from
Canton, OH
Click here to add this to my saved trials